The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2023 | Key radiotherapy updates at ASCO GI 2023
Manisha Palta, MD, Duke University, Durham, NC, provides an overview of radiotherapy trials presented at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium, including findings from the Phase III NRG/RTOG 1112 trial (NCT01730937) of stereotactic body radiation therapy (SBRT) and sorafenib in patients with hepatocellular carcinoma (HCC). Dr Palta additionally highlights studies assessing palliative radiotherapy in metastatic HCC, as well as short course radiation in rectal cancer. This interview took place at the ASCO 2023 GI Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
